Online citations, reference lists, and bibliographies.
← Back to Search

Synthesis And Characterization Of Hyaluronic Acid Coated Manganese Dioxide Microparticles That Act As ROS Scavengers.

J. Bizeau, C. Tapeinos, C. Marella, A. Larrañaga, A. Pandit
Published 2017 · Chemistry, Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
Atherosclerosis is a chronic inflammatory disease of the arterial wall that leads to cardiovascular diseases which are the major cause of deaths worldwide. There is currently no treatment that can stop or reverse the disease. However, the use of microparticles with anti-inflammatory properties could represent a promising treatment. Herein, spherical microparticles with a core-shell structure and an average diameter of 1μm were synthesized. The microparticles were comprised of a MnCO3 and MnO2 core and a 4-arm PEG-amine cross-linked shell of hyaluronic acid. The HA-Mn-SM microparticles were loaded with D-α-tocopherol (vitamin-E) (TOC), to fabricate a targeted biocompatible delivery platform for the treatment of atherosclerotic inflamed cells. Loading and release studies of TOC demonstrated a lactic acid concentration dependant controlled release profile of the HA-Mn-SM mimicking the atherosclerotic environment where lactic acid is over-produced. The microparticles exhibited a high scavenging ability towards H2O2 in addition to the controlled generation of O2. The optimal results were obtained for 250μg/mL microparticles which in the presence of 1000μM H2O2 resulted in the scavenging of almost all the H2O2. Our results demonstrate that 50μg/mL of microparticles scavenged continuously produced H2O2 up to a concentration of 1000μM, a characteristic that demonstrates the sustained therapeutic effect of the HA-Mn-SM microparticles in an environment that mimics that of inflamed tissues. Our results indicate the potential use of HA-Mn-SM as a novel platform for the treatment of atherosclerosis. In vitro studies confirmed that the microparticles are not cytotoxic at concentrations up to 250μg/mL and for 72h. These preliminary results indicate the potential use of HA-Mn-SM as a novel drug delivery system for atherosclerotic tissues.
This paper references
10.1002/adma.201505376
Physical, Chemical, and Biological Structures based on ROS-Sensitive Moieties that are Able to Respond to Oxidative Microenvironments.
C. Tapeinos (2016)
Chemosphere
S.-H. Do (2009)
10.1515/9783111576855-015
J
Seguin Hen (1824)
Chem Commun (Camb)
J. Huang (2010)
Part
X. Yang (2015)
10.1002/ADMA.200701231
Controlled Preparation of MnO2 Hierarchical Hollow Nanostructures and Their Application in Water Treatment
Jinbo Fei (2008)
10.1001/JAMA.297.5.499
Statins, high-density lipoprotein cholesterol, and regression of coronary atherosclerosis.
S. Nicholls (2007)
Free Radical Bio
P. Bozaykut (2014)
Med
S. J. Nicholls (2007)
10.1136/bmj.326.7404.1423
Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis
M. Law (2003)
10.1300/j120v46n95_09
VET
Buffhirko (2006)
10.1016/j.ijbiomac.2016.04.070
Development of chitosan nanoparticles coated with hyaluronic acid for topical ocular delivery of dexamethasone.
M. A. Kalam (2016)
10.1161/HC0902.104353
Inflammation and Atherosclerosis
P. Libby (2002)
10.1006/JCAT.1998.2061
Studies of Decomposition of H2O2over Manganese Oxide Octahedral Molecular Sieve Materials
Hua Zhou (1998)
10.1038/123373a0
Chemistry
J. R (1929)
Angew Chem Int Ed Engl
H. B. Na (2007)
10.1021/nn1019779
Biocompatible and pH-sensitive PLGA encapsulated MnO nanocrystals for molecular and cellular MRI.
Margaret F Bennewitz (2011)
10.1016/S0140-6736(04)16962-6
CIRCULATION
A. Wear (2004)
10.1161/01.CIR.0000131514.71167.2e
Inflammation in Atherosclerosis and Implications for Therapy
R. Paoletti (2004)
10.1198/000313001750358509
APPL
A. Glen (2001)
BMJ
M. R. Law (2003)
10.1161/CIRCULATIONAHA.106.174516
AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update: endorsed by the National Heart, Lung, and Blood Institute.
S. Smith (2006)
10.17221/1930-VETMED
Hyaluronic acid (hyaluronan): a review
J. Necas (2018)
Colloid Surface A
W. Zhang (2007)
10.1016/S0735-1097(01)01682-5
AHA/ACC Guidelines for Preventing Heart Attack and Death in Patients With Atherosclerotic Cardiovascular Disease: 2001 update. A statement for healthcare professionals from the American Heart Association and the American College of Cardiology.
S. Smith (2001)
10.1063/1.4914015
Capture and release of cancer cells using electrospun etchable MnO2 nanofibers integrated in microchannels
Huiqin Liu (2015)
10.1161/01.CIR.0000075572.40158.77
Exercise and physical activity in the prevention and treatment of atherosclerotic cardiovascular disease: a statement from the Council on Clinical Cardiology (Subcommittee on Exercise, Rehabilitation, and Prevention) and the Council on Nutrition, Physical Activity, and Metabolism (Subcommittee on Ph
P. Thompson (2003)
Biosens
X.-L. Luo (2004)
10.1016/S0140-6736(08)61262-3
Inflammation
O. Parnes (2008)
Adv
C. R. Gordijo (2015)
Coll
S. C. Smith (2001)
10.1515/9783111548050-024
M
M. Sankar (1824)
Colloids Surf B Biointerfaces
C. Tapeinos (2016)
Int J Pharm
E. K. Efthimiadou (2014)
10.1016/S0926-860X(98)00430-X
Promotion of the hydrogen peroxide decomposition activity of manganese oxide catalysts
M. A. Hasan (1999)
J Am Chem Soc
D. Pan (2008)
Mater
S. M. Pourmortazavi (2012)
Int
M. A. Kalam (2016)
10.1179/174328408x369933
Biomaterials
R. Misra (2008)
ACS Nano
M. F. Bennewitz (2011)
ACS Nano
P. Prasad (2014)
10.1016/j.ijpharm.2013.11.037
Dynamic in vivo imaging of dual-triggered microspheres for sustained release applications: synthesis, characterization and cytotoxicity study.
E. K. Efthimiadou (2014)
10.1039/c0cc01041c
HSA coated MnO nanoparticles with prominent MRI contrast for tumor imaging.
J. Huang (2010)
10.1136/sbmj.050390
Nanomedicine
Dan J. Martin (2005)
Health statistics - Atlas on mortality
E. E. Comission (2009)
10.1016/j.freeradbiomed.2014.02.017
Effects of vitamin E on peroxisome proliferator-activated receptor γ and nuclear factor-erythroid 2-related factor 2 in hypercholesterolemia-induced atherosclerosis.
Perinur Bozaykut (2014)
10.1016/J.MATERRESBULL.2011.12.048
Statistical optimization of experimental parameters for synthesis of manganese carbonate and manganese oxide nanoparticles
S. M. Pourmortazavi (2012)
10.1016/j.canlet.2012.07.002
Hyaluronic acid-coated nanostructured lipid carriers for targeting paclitaxel to cancer.
Xiao-yan Yang (2013)
Research on the formation mechanism of composites from lignocelluloses and CaCO3 / Mater. Sci. Eng. C-Mater. Biol. Appl.
Lian-Hua Fu (2014)
10.1016/j.msec.2014.01.024
pH- and thermo-responsive microcontainers as potential drug delivery systems: Morphological characteristic, release and cytotoxicity studies.
E. K. Efthimiadou (2014)
10.1007/BF00917314
Hydrogen peroxide-induced cell and tissue injury: Protective effects of Mn2+
J. Varani (2004)
10.1016/j.biomaterials.2013.03.065
Hyaluronic acid (HA) presentation as a tool to modulate and control the receptor-mediated uptake of HA-coated nanoparticles.
Abdulaziz Almalik (2013)
10.1016/J.BIOS.2003.11.019
A novel glucose ENFET based on the special reactivity of MnO2 nanoparticles.
X. Luo (2004)
10.1161/01.CIR.0000020190.45892.75
AHA Guidelines for Primary Prevention of Cardiovascular Disease and Stroke: 2002 Update: Consensus Panel Guide to Comprehensive Risk Reduction for Adult Patients Without Coronary or Other Atherosclerotic Vascular Diseases. American Heart Association Science Advisory and Coordinating Committee.
T. A. Pearson (2002)
10.1002/chem.201404625
MnO2-modified persistent luminescence nanoparticles for detection and imaging of glutathione in living cells and in vivo.
N. Li (2014)
Adv Mater
C. Tapeinos (2016)
Adv
Y. Chen (2014)
10.1002/PPSC.201400092
Glutathione‐Mediated Degradation of Surface‐Capped MnO2 for Drug Release from Mesoporous Silica Nanoparticles to Cancer Cells
Xue Yang (2015)
10.4067/S0716-97602006000100006
Homeostatic and toxic mechanisms regulating manganese uptake, retention, and elimination.
J. Roth (2006)
10.1016/j.colsurfb.2016.08.019
Sustained release profile of quatro stimuli nanocontainers as a multi sensitive vehicle exploiting cancer characteristics.
C. Tapeinos (2016)
Int
L. Zhang (2009)
10.1002/ANIE.200604775
Development of a T1 contrast agent for magnetic resonance imaging using MnO nanoparticles.
Hyon Bin Na (2007)
10.1002/adma.201402572
Break-up of two-dimensional MnO2 nanosheets promotes ultrasensitive pH-triggered theranostics of cancer.
Y. Chen (2014)
10.1002/ADFM.201404511
Design of Hybrid MnO2‐Polymer‐Lipid Nanoparticles with Tunable Oxygen Generation Rates and Tumor Accumulation for Cancer Treatment
C. Gordijo (2015)
10.1021/ja801482d
Ligand-directed nanobialys as theranostic agent for drug delivery and manganese-based magnetic resonance imaging of vascular targets.
D. Pan (2008)
Biol
J. A. Roth (2006)
10.1016/J.COLSURFA.2007.04.022
Promotion of H2O2 decomposition activity over β-MnO2 nanorod catalysts
W. Zhang (2007)
10.1016/j.biomaterials.2015.02.089
Hyaluronic acid nanoparticles for active targeting atherosclerosis.
G. Lee (2015)
10.1021/nn405773r
Multifunctional albumin-MnO₂ nanoparticles modulate solid tumor microenvironment by attenuating hypoxia, acidosis, vascular endothelial growth factor and enhance radiation response.
P. Prasad (2014)
10.1016/j.chemosphere.2008.11.075
Hydrogen peroxide decomposition on manganese oxide (pyrolusite): kinetics, intermediates, and mechanism.
Si-Hyun Do (2009)
10.1161/CIR.0000000000000350
Heart Disease and Stroke Statistics—2016 Update: A Report From the American Heart Association
D. Mozaffarian (2016)



This paper is referenced by
Semantic Scholar Logo Some data provided by SemanticScholar